Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyGarenoxacin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Garenoxacin
- Accession Number
- DB06160
- Type
- Small Molecule
- Groups
- Investigational
- Description
Garenoxacin (INN) is a quinolone antibiotic undergoing regulatory review for the treatment of gram-positive and gram-negative bacterial infections. [Wikipedia]
- Structure
- Synonyms
- desquinolone
- Garenoxacin
- garenoxacino
- External IDs
- T-3811
- Product Ingredients
Ingredient UNII CAS InChI Key Garenoxacin Mesylate OXI6EF55FR 223652-90-2 IGTHEWGRXUAFKF-NVJADKKVSA-N - Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antineoplastic Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Fluoroquinolones
- Moderate Risk QTc-Prolonging Agents
- QTc Prolonging Agents
- Quinolines
- Quinolones
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- UNII
- V72H9867WB
- CAS number
- 194804-75-6
- Weight
- Average: 426.42
Monoisotopic: 426.139113458 - Chemical Formula
- C23H20F2N2O4
- InChI Key
- NJDRXTDGYFKORP-LLVKDONJSA-N
- InChI
- InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
- IUPAC Name
- 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- SMILES
- C[C@H]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O
Pharmacology
- Indication
Investigated for use/treatment in bacterial infection.
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Garenoxacin. (S)-Warfarin The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Garenoxacin. 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Garenoxacin. 3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Garenoxacin. 4-hydroxycoumarin The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Garenoxacin. 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Garenoxacin. 7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Garenoxacin. 7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Garenoxacin. 8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Garenoxacin. 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Garenoxacin. - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- ChemSpider
- 110579
- ChEBI
- 131716
- ChEMBL
- CHEMBL215303
- Wikipedia
- Garenoxacin
- ATC Codes
- J01MA19 — Garenoxacin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0232 mg/mL ALOGPS logP 1.71 ALOGPS logP 1.62 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 6.05 ChemAxon pKa (Strongest Basic) 8.88 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 78.87 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 110.37 m3·mol-1 ChemAxon Polarizability 42.39 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Isoindolines / Isoindoles / Aralkylamines / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Amino acids show 10 more
- Substituents
- Quinoline-3-carboxylic acid / Dihydroquinolone / Dihydroquinoline / Isoindoline / Isoindole / Isoindole or derivatives / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aralkylamine / Benzenoid show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- Curator comments
- This drug is a fluoroquinolone, and these agents are known to inhibit CYP1A2.
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Rodighiero V: Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999 Nov;37(5):399-431. [PubMed:10589374]
- Bril F, Gonzalez CD, Di Girolamo G: Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf. 2010 Jan;5(1):85-92. [PubMed:20210724]
- Zhang L, Wei MJ, Zhao CY, Qi HM: Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008 Dec;29(12):1507-14. doi: 10.1111/j.1745-7254.2008.00908.x. [PubMed:19026171]
Drug created on March 19, 2008 10:14 / Updated on December 16, 2018 06:52